Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
standard-titer COVID-19 convalescent plasma
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Administration
- Intravenous
01
Overview
CCP2-University of North Carolina, Chapel Hill-COVID-19 refers to standard-titer COVID-19 convalescent plasma (CCP) evaluated in the CoronaVirus Inactivating Plasma (CoVIP) study (NCT04524507) at the University of North Carolina at Chapel Hill. This biologic therapy consists of plasma collected from individuals who have recovered from SARS-CoV-2 infection, containing polyclonal neutralizing antibodies. In the context of the IGHID 12021 phase 2 trial, CCP2 specifically designated the standard-titer arm, where the plasma units had neutralizing antibody titers between 1:160 and 1:640. The therapy works by providing passive immunity; the antibodies bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells and facilitating viral clearance. The study was designed to compare the efficacy and safety of these standard-titer units against high-titer units in hospitalized adults with early COVID-19 symptoms.
- Other names
- CCP2-University of North Carolina, Chapel Hill-COVID-19Standard-titer Convalescent COVID-19 plasmaCOVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasma
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on standard-titer COVID-19 convalescent plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on standard-titer COVID-19 convalescent plasma.